Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(33%)

Results Posted

50%(1 trials)

Phase Distribution

Ph not_applicable

33%

Ph phase_1

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Detailed Status

Completed2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 31 (33.3%)

N/A1 (33.3%)

Trials by Status

completed267%

active_not_recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

active_not_recruitingphase_3

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

NCT05600426

completednot_applicable

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

NCT02845596

completedphase_1

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

NCT00448357

Clinical Trials (3)

Showing 3 of 3 trials

NCT05600426Phase 3

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Active Not Recruiting

NCT02845596Not Applicable

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Completed

NCT00448357Phase 1

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3